🔎 Trials Near Me

Gara Jalqabaatti › Baayyee Ulfaataa › Texas › Austin

Qorannoo klinikaalii Baayyee Ulfaataa Austin, TX keessatti

Qorannoo 18 Baayyee Ulfaataa f Austin fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.

Takkalaa qorannoo (Ingiliffa)

Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Namoota walitti qabaa jiraSadarkaa 3
  • Elligo Clinical Research Center, Austin
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07684235

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

Namoota walitti qabaa jiraSadarkaa 3
  • Elligo Clinical Research Center, Austin
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07684144

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Namoota walitti qabaa jiraSadarkaa 3
  • Austin Heart, Austin
  • Velocity Clinical Research - Austin, Austin
Umuriin 45 hanga 99 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT07037433

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Namoota walitti qabaa jiraSadarkaa 2
  • Elligo Clinical Research Center /ID# 282166, Austin
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT07752979

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Namoota walitti qabaa jiraSadarkaa 3
  • IMA Clinical Research Austin, Austin
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07794579

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Namoota walitti qabaa jiraSadarkaa 3
  • Texas Diabetes & Endocrinology, Austin
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT07668414

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Namoota walitti qabaa jiraSadarkaa 3
  • Dell Children's Medical Center - PIN, Austin
Umuriin 6 hanga 17 · Saalaa hunda · Haaromfame 24-Ful-2026 · NCT06672549

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Namoota walitti qabaa jiraSadarkaa 3
  • IMA Clinical Research Austin, Austin
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07282600

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Namoota walitti qabaa jiraSadarkaa 2
  • IMA Clinical Research Austin, Austin
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07589608

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Namoota walitti qabaa jiraSadarkaa 3
  • FutureSearch Trials of Neurology, Austin
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 22-Ful-2026 · NCT07369011

Semaglutide for Post-Smoking Cessation Weight Management

Namoota walitti qabaa jiraSadarkaa 2Hojjettoota fayyaa simatamoo
  • The University of Texas at Austin, Austin
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT06173778

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Namoota walitti qabaa jiraSadarkaa 3
  • AURORA-2 Clinical Site, Austin
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07743450

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Namoota walitti qabaa jiraSadarkaa 3
  • AURORA-1 Clinical Site, Austin
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT07743463

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Namoota walitti qabaa jiraSadarkaa 3Hojjettoota fayyaa simatamoo
  • ACCOMPLISH-2 Research Site, Austin
Umuriin 18 hanga 79 · Saalaa hunda · Haaromfame 11-Ful-2026 · NCT07654374

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Namoota walitti qabaa jiraSadarkaa 2
  • IMA Clinical Research Austin, Austin
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 08-Ful-2026 · NCT06143956

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

Namoota walitti qabaa jiraSadarkaa 3
  • ACCOMPLISH-1 Research Site, Austin
  • ACCOMPLISH-1 Research Site, Austin
Umuriin 18 hanga 79 · Saalaa hunda · Haaromfame 10-Hag-2026 · NCT07654361

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Namoota walitti qabaa jiraSadarkaa 1
  • Elligo Clin Res Centre, Austin
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 25-Wax-2026 · NCT07607587

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

Namoota walitti qabaa jiraSadarkaa 1
  • Corxel Investigational Site, Austin
Umuriin 18 hanga 55 · Dubartoota · Haaromfame 17-Wax-2026 · NCT07652047

Qorannoo Baayyee Ulfaataa magaalota biroo keessatti

Qorannoo biroo Austin keessatti

Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.